Pubblicazioni

  1. Sergi D, Zauli E, Casciano F, Secchiero P, Zauli G, Fields M, Melloni E. Palmitic Acid Induced a Long-Lasting Lipotoxic Insult in Human Retinal Pigment Epithelial Cells, which Is Partially Counteracted by TRAIL. Antioxidants (Basel). 2022 Nov 26;11(12):2340. doi: 10.3390/antiox11122340.
  2. Pisanti S, Rimondi E, Pozza E, Melloni E, Zauli E, Bifulco M, Martinelli R, Marcuzzi A. Prenylation Defects and Oxidative Stress Trigger the Main Consequences of Neuroinflammation Linked to Mevalonate Pathway Deregulation. Int J Environ Res Public Health. 2022 Jul 25;19(15):9061. doi: 10.3390/ijerph19159061.
  3. Marcuzzi A, Rimondi E, Melloni E, Zennaro F, Sonzogni A, Leo S, Maximova N. Acute Neurological Involvement after    Donor Lymphocyte Infusion for Post‐Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy‐Related CNS Toxicity? Int. J. Mol. Sci. 2022, 23, 3553. https:// doi.org/10.3390/ijms23073553
  4. Marcuzzi A, Rimondi E, Melloni E, Gonelli, A, Grasso AG, Barbi E, Maximova N. New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib. Pharmaceuticals 2022, 15, 374. https://doi.org/10.3390/ ph15030374
  5. Melloni E, Marchesi E, Preti L, Casciano F, Rimondi E, Romani A, Secchiero P, Navacchia ML, Perrone D. Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids. Molecules. 2022; 12;27(2):471. doi: 10.3390/molecules27020471.
  6. Marcuzzi A*, Melloni E*, Giorgio Zauli G, Romani A, Secchiero P, Maximova N, Rimondi E. Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity. Int. J. Mol. Sci. 2021;22, 11241. doi: 10.3390/ijms222011241.
  7. Rimondi E, Valencic E, Tommasini A, Secchiero P, Melloni E, Marcuzzi A. Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation, Biomolecules, 2021;11, 1438. doi: 10.3390/biom11101438.
  8. Rimondi E, Melloni E, Romani A, Tisato V, Casciano F, Rigolin GM, Milani D, Celeghini C, Zauli G, Secchiero P, Voltan R. Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors. Curr Oncol. 2021;28(4):2439-2451. doi: 10.3390/curroncol28040223.
  9. Piscianz E, Tesser A, Rimondi E, Melloni E, Celeghini C, Marcuzzi A. MitoQ Is Able to Modulate Apoptosis and Inflammation. Int J Mol Sci. 2021;22(9):4753. doi: 10.3390/ijms22094753.
  10. Ziliotto N, Lamberti N, Manfredini F, Straudi S, Tisato V, Carantoni M, Melloni E, Secchiero P, Basaglia N, Bernardi F, Marchetti G. Baseline and overtime variation of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients. J Neuroimmunol. 2021; 352:577473. doi: 10.1016/j.jneuroim.. 2020.577473.
  11. Rimondi E, Marcuzzi A, Casciano F, Tornese G, Pellati A, Toffoli B, Secchiero P, Melloni E. Role of vitamin D in the pathogenesis of atheromatosis. Nutr Metab Cardiovasc Dis. 2021 Jan 4;31(1):344-353. doi: 10.1016/j.numecd.2020.08.03.
  12. Ferrari D, Vuerich M, Casciano F, Longhi MS, Melloni E, Secchiero P, Zech A, Robson SC, Müller T, Idzko M. Eosinophils and Purinergic Signaling in Health and Disease. Front Immunol. 2020;11:1339. doi: 10.3389/fimmu.2020.01339.ati
  13. Astolfi M, Rispoli G, Anania G, Nevoso V, Artioli E,  Landini N , Benedusi M, Melloni E, Secchiero P, Tisato V, Zonta G, Cesare Malagù C. Colorectal Cancer Study with Nanostructured  Sensors: Tumor Marker Screening of Patient Biopsies. Nanomaterials. 2020; 10(4): E606. doi: 10.3390/nano10040606.
  14. Tisato V, Romani A, Tavanti E, Melloni E, Milani D, Bonaccorsi G, Sanz JM, Gemmati D, Passaro A, Cervellati C. Crosstalk between Adipokines and Paraoxonase 1: a new potential axis linking oxidative stress and inflammation. Antioxidants (Basel). 2019; 8(8). pii: E287. doi: 10.3390/antiox8080287.
  15. Bernardi S, Voltan R, Rimondi E, Melloni E, Milani D, Cervellati C, Gemmati D, Celeghini C, Secchiero P, Zauli G, Tisato V. TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?Clin Sci (Lond). 2019; 133(10):1145-1166. doi: 10.1042/CS20181116.
  16. Simioni C, Martelli AM, Zauli G, Melloni E, Neri LM. Targeting mTOR in Acute Lymphoblastic Leukemia. Cells. 2019; 8(2). pii: E190. doi:10.3390/cells8020190.
  17. Arcidiacono MV, Rimondi E, Maietti E, Melloni E, Tisato V, Gallo S, Valdivielso JM, Fernández E, Betriu À, Voltan R, Zauli G, Volpato S, Secchiero P. Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. PLoS One. 2018 Sep 11;13(9):e0203716. doi: 10.1371/journal.pone.0203716.
  18. Tisato V, Gallo S, Melloni E, Celeghini C, Passaro A, Zauli G, Secchiero P, Bergamini C, Trentini A, Bonaccorsi G, Valacchi G, Zuliani G, Cervellati C. TRAIL and ceruloplasmin inverse correlation as a representative crosstalk between inflammation and oxidative stress. Mediat Inflamm. 2018; 26;2018:9629537. doi: 10.1155/2018/9629537
  19. Secchiero P, Voltan R, Rimondi E, Melloni E, Athanasakis E, Tisato V, Gallo S, Rigolin GM, Zauli G. The γ-secretase inhibitors enhance the anti-leukemic activity of Ibrutinib in B-CLL cells. Oncotarget. 2017; 8(35):59235-59245. doi:10.18632/oncotarget.19494
  20. Voltan R, Rimondi E, Melloni E, Rigolin GM, Casciano F, Arcidiacono MV, Celeghini C, Cuneo A, Zauli G, Secchiero P. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. Oncotarget. 2016; 7(43):70623-70638. doi:10.18632/oncotarget.12139
  21. Voltan R, Rimondi E, Melloni E, Gilli P, Bertolasi V, Casciano F, Rigolin GM, Zauli G, Secchiero P. Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. Oncotarget. 2016; 7(14):18965-77. doi: 10.18632/oncotarget.7879.
  22. Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S, Fantinati A, Salvadori S, Guerrini R, Secchiero P, Zauli G. Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. J Med Chem. 2016; 59(1):147-56. doi:10.1021/acs.jmedchem.5b01165
  23. Tisato V, Perri P, Rimondi E, Melloni E, Lamberti G, Milani D, Secchiero P, Zauli G. Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy. Mediat Inflamm. 2015; 2015:942948. doi:10.1155/2015/942948
  24. Agnoletto C, Brunelli L, Melloni E, Pastorelli R, Casciano F, Rimondi E, Rigolin GM, Cuneo A, Secchiero P, Zauli G. The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21  pathway. Oncotarget. 2015; 6(4):2385-96. doi:10.18632/oncotarget.2960
  25. Athanasakis E*, Melloni E*, Gian Matteo Rigolin GM, Agnoletto C, Voltan R, Vozzi D, Piscianz E, Segat L, Dal Monego S, Cuneo A, Secchiero P, Zauli G. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. Oncotarget. 2014; 5(24):12635-45. doi:10.18632/oncotarget.2211
  26. Agnoletto C*, Melloni E*, Casciano F, Rigolin GM, Rimondi E, Celeghini C, Brunelli L, Cuneo A, Secchiero P, Zauli G. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. Oncotarget. 2014; 5(12):4347-60. doi:10.18632/oncotarget.2018
  27. Zauli G, Tisato V, Melloni E, Volpato S, Cervellati C, Bonaccorsi G, Radillo O, Marci R, Secchiero P. Inverse correlation between circulating levels of TNF-related apoptosis inducing ligand and 17-β estradiol. J Clin Endocrinol Metab. 2014; 99(4):E659-64. doi:10.1210/jc.2013-4193
  28. Secchiero P, Toffoli B, Melloni E, Agnoletto C, Monasta L, Zauli G. The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. Acta Diabetol. 2013; 50(6):899-906. doi:10.1007/s00592-013-0476-8
  29. Rimondi E, Secchiero P, Melloni E, Grill V, Zauli G. Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl- 1. Invest New Drugs. 2013; 31(3):780-6. doi:10.1007/s10637-012-9903-x
  30. Secchiero P, Rimondi E, di Iasio MG, Agnoletto C, Melloni E, Volpi I, Zauli G. C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1-Dependent Pathway. Clin Cancer Res. 2013; 19(8):1949-59. doi:10.1158/1078-0432.CCR-12-3027
  31. Melloni E, Zauli G, Celeghini C, Volpi I, Secchiero P. Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells. Nutrition. 2013; 29(1):3 32-7. doi:10.1016/j.nut.2012.07.013
  32. Comar M, Cuneo A, Maestri I, Melloni E, Pozzato G, Soffritti O, Secchiero P, Zauli G. Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. J Clin Virol. 2012; 55(4):367-9. doi:10.1016/j.jcv.2012.08.011
  33. Di Iasio MG, Norcio A, Melloni E, Zauli G. SOCS1 is significantly up-regulates in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. Invest New Drugs. 2012; 30(6):2403-6. doi:10.1007/s10637-011-9786-2
  34. Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P. The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status. Haematologica. 2012; 97(11): 1722-30. doi:10.3324/haematol.2012.062083
  35. Secchiero P, Melloni E, Voltan R, Norcio A, Celeghini C, Zauli G. Mcl-1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol. 2012; 157, 493-516. doi:10.1111/j.1365-2141.2012.09042.x
  36. Carinci F, Monasta L, Rubini C, Stramazzotti D, Palmieri A, Melloni E, Knowles A, Ronfani L, Zauli G, Secchiero P. The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Invest New Drugs. 2012; 30: 810-8. doi:10.1007/s10637-010-9586-0
  37. Sollazzo V, Fanali S,  Masiero E, Girardi A, Farinella F, Melloni E, Pezzetti F, Iaccarino C, Zauli G, Carinci F. Peptide-15 stimulates pulp stem cells towards osteoblasts differentation. Eur J Inflamm. 2011; 9, 1.
  38. Sollazzo V, Fanali S,  Masiero E, Girardi A, Farinella F, Melloni E, Pezzetti F, Iaccarino C, Zauli G, Carinci F. Tricalcium phosphate stimulates adipose tissue-derived stem cells towards  osteoblasts differentation. Eur J Inflamm. 2011; 9, 1.
  39. Secchiero P, Perri P, Melloni E, Martini A, Lamberti G, Sebastiani A, Zauli G. Decreased levels of soluble TNF-related apoptosis-inducing ligand (TRAIL) in the conjunctival sac fluid of patients with diabetes affected by proliferative retinopathy. Diabetic Med. 2011; 28(10):1277-8. doi:10.1111/j.1464-5491.2010.03202.x
  40. Zauli G, Voltan R, di Iasio MG, Bosco R, Melloni E, Sana ME, Secchiero P. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res. 2011; 17(9):2712-24. doi:10.1158/1078-0432.CCR-10-3244
  41. Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G. Fine tuning of proteinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini-Rev Med Chem. 2011; 11(3):185-99. doi:10.2174/138955711795049899
  42. Zauli G, Voltan R, Bosco R, Melloni E, Marmiroli S, Rigolin GM, Cuneo A, Secchiero P. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. Clin Cancer Res. 2011; 17(4):762-70. doi:10.1158/1078-0432.CCR-10-2572
  43. Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L, Bosco R, Ingrao S, Zavan B, Zauli G. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One. 2010; 5(6):e11140. doi:10.1371/journal.pone.0011140
  44. Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, Zauli G. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. Clin Cancer Res. 2010; 16(6):1824-33. doi:10.1158/1078-0432.CCR-09-3031
  45. Voltan R, Celeghini C, Melloni E, Secchiero P, Zauli G. Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity. Br J Haematol. 2010; 148(6):957-61. doi:10.1111/j.1365-2141.2009.08018.x
  46. Secchiero P, di Iasio MG, Melloni E, Voltan R, Celeghini C, Tiribelli M, Dal Bo M, Gattei V, Zauli G. The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. Leukemia. 2010; 24(2):480-3. doi:10.1038/leu.2009.215
  47. Secchiero P, Melloni E, di Iasio MG, Tiribelli M, Rimondi E, Corallini F, Gattei V, Zauli G. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood. 2009; 113(18):4300-8. doi:10.1182/blood-2008-11-187708
  48. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci. 2009; 66(5):841-51. doi:10.1007/s00018-008-8536-x
  49. Secchiero P, Sblattero D, Chiaruttini C, Melloni E, Macor P, Zorzet S, Tripodo C, Tedesco F, Marzari R, Zauli G. Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity. Int J Immunopathol Pharmacol. 2009; 22(1):73-83. doi:10.1177/039463200902200109
  50. Secchiero P, Lamberti G, Corallini F, Melloni E, Guarnotta C, Sebastiani A, Zauli G. Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye. J Cell Physiol. 2009; 218(1):199-204. doi:10.1002/jcp.21589
  51. Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow  multipotent stromal cells. Stem Cells. 2008; 26(11):2955-63. doi:10.1634/stemcells.2008-0512
  52. Mischiati C, Melloni E, Corallini F, Milani D, Bergamini C, Vaccarezza M. Potential role of PKC inhibitors in the treatment of hematological malignancies. Curr Pharm Design. 2008; 14(21):2075-84. doi:10.2174/138161208785294618
  53. Secchiero P, Melloni E, Tiribelli M, Gonelli A, Zauli G. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. J Leukoc Biol. 2008; 83(2):434-7. doi:10.1189/jlb.0707459
  54. Secchiero P, Zerbinati C, Melloni E, Milani D, Campioni D, Fadda R, Tiribelli M, Zauli G. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia. 2007; 9(10):853-61. doi:10.1593/neo.07523
  55. Secchiero P, di Iasio MG, Gonelli A, Barbarotto E, Melloni E, Tiribelli M, Chiaruttini C, Zauli G. Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. J Cell Physiol. 2007; 213(1):229-36. doi:10.1002/jcp.21116
  56. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab. 2007; 8(4):395-403. doi:10.2174/138920007780655432
  57. Secchiero P, Corallini F, Barbarotto E, Melloni E, di Iasio MG, Tiribelli M, Zauli G. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol. 2006; 207(1):158-64. doi:10.1002/jcp.20547
  58. Melloni E, Secchiero P, Celeghini C, Campioni D, Grill V, Guidotti L, Zauli G. Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. J Cell Physiol. 2005; 204(3):975-82. doi:10.1002/jcp.20358
  59. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, Zauli G. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol. 2005; 166(2):557-63. doi:10.1016/S0002-9440(10)62277-8
  60. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Melloni E, Vitale M. The response of human natural killer cells to interleukin-2. J Endocrinol Invest. 2004; 27(6 Suppl):146-50.
  61. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood. 2004; 104(7):2044-50. doi:10.1182/blood-2004-03-1196
  62. Zamai L, Burattini S, Luchetti F, Canonico B, Ferri P, Melloni E, Gonelli A, Guidotti L, Papa S, Falcieri E. In vitro apoptotic cell death during erythroid differentiation. Apoptosis. 2004; 9(2):235-46. doi:10.1023/B:APPT.0000018805.63663.a5
  63. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Iacone A, Zauli G. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood. 2004; 103(2):517-22. doi:10.1182/blood-2003-06-2137
  64. Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. J Leukoc Biol. 2003; 74(2):223-32. doi:10.1189/jlb.0103004
  65. Ponti C, Gibellini D, Boin F, Melloni E, Manzoli FA, Cocco L, Zauli G, Vitale M. Role of CREB transcription factor in c-fos activation in natural killer cells. Eur J Immunol. 2002; 32(12):3358-65. doi: 10.1002/1521-4141(200212)32:12<3358::AID-IMMU3358>3.0.CO;2-Q
  66. Secchiero P, Gonelli A, Ciabattoni G, Melloni E, Grill V, Rocca B, Delbello G, Zauli G. TNF-related apoptosis-inducing ligand (TRAIL) up-regulates cyclooxygenase (COX)-1 activity and PGE(2) production in cells of the myeloid lineage. J Leukoc Biol. 2002; 72(5):986-94. doi:10.1002/1521-4141(2002012)32:12<3358::AID-IMMU3358>3.0.CO;2-8
  67. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani D, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood. 2002; 100(7):2421-9. doi:10.1182/blood-2002-01-0047
  68. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002; 99(11):7634-9. doi:10.1073/pnas.112202999
  69. Zamai L, Canonico B, Luchetti F, Ferri P, Melloni E, Guidotti L, Cappellini A, Cutroneo G, Vitale M, Papa S. Supravital exposure to propidium iodide identifies apoptosis on adherent cells. Cytometry. 2001; 44(1):57-64. doi: 10.1002/1097-0320(20010501)44:1<57::AID-CYTO1082>3.3.CO;2-F
  70. Gibellini D, Re MC, Ponti C, Celeghini C, Melloni E, La Placa M, Zauli G. Extracellular Tat activates c-fos promoter in low serum-starved CD4+ T cells. Br J Haematol. 2001; 112(3):663-70. doi:10.1046/j.1365-2141.2001.02576.x

 

*These authors contributed equally to the work